TargetMol

BAY 41-2272

Product Code:
 
TAR-T6775
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T6775-1mg1mg£98.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6775-2mg2mg£108.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6775-1mL1 mL * 10 mM (in DMSO)£131.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6775-5mg5mg£131.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6775-10mg10mg£179.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6775-25mg25mg£301.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6775-50mg50mg£438.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6775-100mg100mg£611.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
BAY 41-2272 is a direct and NO-independent soluble guanylate cyclase (sGC) stimulator.
CAS:
256376-24-6
Formula:
C20H17FN6
Molecular Weight:
360.396
Pathway:
GPCR/G Protein
Purity:
0.9986
SMILES:
Nc1nc(ncc1C1CC1)-c1nn(Cc2ccccc2F)c2ncccc12
Target:
Guanylate cyclase

References

Tuttle TR, et al. The cyclic GMP/protein kinase G pathway as a therapeutic target in head and neck squamous cell carcinoma. Cancer Lett. 2016 Jan 28;370(2):279-85. Nunes KP, et al. J Pharmacol Exp Ther. 2015, 353(2), 330-339. Soeiro-Pereira PV, et al. Mem Inst Oswaldo Cruz. 2015, 110(1), 75-85. Stasch JP, et al. Nature. 2001, 410(6825), 212-215. Kalsi JS, et al. J Urol. 2003, 169(2), 761-766. Becker EM, et al. BMC Pharmacol. 2001, 1, 13.